CORRECTED-CSL signs licensing deal with Eli Lilly for clazakizumab
ليلي، إيلاي آند كو -0.11%
Carlisle Companies Incorporated -0.96%
Eli Lilly and Company LLY | 903.99 | -0.11% |
Carlisle Companies Incorporated CSL | 347.26 | -0.96% |
Removes incorrect reference to a kidney disease treatment deal from the headline
Feb 18 (Reuters) - Australia's CSL CSL.AX said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co LLY.N, granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease.